GRI Bio to Present at the 2024 European Respiratory Congress
GRI Bio, Inc. (GRI)
Company Research
Source: GlobeNewswire
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 European Respiratory Congress (ERS) being held September 7-11, 2024 in Vienna, Austria. Details of the poster presentation are as follows: Title: Type 1 Invariant Natural Killer T Cells Drive Lung FibrosisPresenter: Emily Calamita of Dr. Adam Byrne’s laboratory, Imperial College LondonPoster Number: PA3381Session: Novel Insights in the Pathogenesis of Pulmonary Fibrosis Date and Time: September 9, 2024, from 12:30 - 2:00 PM CEST For more information about the event, please visit the conference website here. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changin
Show less
Read more
Impact Snapshot
Event Time:
GRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRI alerts
High impacting GRI Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRI
News
- GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) [Yahoo! Finance]Yahoo! Finance
- GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)GlobeNewswire
- GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary FibrosisGlobeNewswire
- GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024GlobeNewswire
- GRI Bio Announces Exercise of WarrantsGlobeNewswire
GRI
Sec Filings
- 11/15/24 - Form 424B3
- 11/14/24 - Form S-3
- 11/14/24 - Form 8-K
- GRI's page on the SEC website